dc.creator | Docobo Pérez, Fernando | |
dc.creator | López Cerero, Lorena | |
dc.creator | López-Rojas, Rafael | |
dc.creator | Egea, P. | |
dc.creator | Domínguez-Herrera, J. | |
dc.creator | Rodríguez-Baño, Jesús | |
dc.creator | Pascual Hernández, Álvaro | |
dc.creator | Pachón Díaz, Jerónimo | |
dc.date.accessioned | 2016-02-24T16:31:14Z | |
dc.date.available | 2016-02-24T16:31:14Z | |
dc.date.issued | 2013-04 | |
dc.identifier.issn | 0066-4804 | es |
dc.identifier.uri | http://hdl.handle.net/11441/36519 | |
dc.description.abstract | Escherichia coli is commonly involved in infections with a heavy bacterial burden. Piperacillin-tazobactam and carbapenems are
among the recommended empirical treatments for health care-associated complicated intra-abdominal infections. In contrast to
amoxicillin-clavulanate, both have reduced in vitro activity in the presence of high concentrations of extended-spectrum -lactamase
(ESBL)-producing and non-ESBL-producing E. coli bacteria. Our goal was to compare the efficacy of these antimicrobials
against different concentrations of two clinical E. coli strains, one an ESBL-producer and the other a non-ESBL-producer, in a
murine sepsis model. An experimental sepsis model {5.5 log10 CFU/g [low inoculum concentration (LI)] or 7.5 log10 CFU/g
[high inoculum concentration (HI)]} using E. coli strains ATCC 25922 (non-ESBL producer) and Ec1062 (CTX-M-14 producer),
which are susceptible to the three antimicrobials, was used. Amoxicillin-clavulanate (50/12.5 mg/kg given intramuscularly
[i.m.]), piperacillin-tazobactam (25/3.125 mg/kg given intraperitoneally [i.p.]), and imipenem (30 mg/kg i.m.) were used. Piperacillin-tazobactam
and imipenem reduced spleen ATCC 25922 strain concentrations (2.53 and 2.14 log10 CFU/g [P < 0.05,
respectively]) in the HI versus LI groups, while amoxicillin-clavulanate maintained its efficacy (1.01 log10 CFU/g [no statistically
significant difference]). Regarding the Ec1062 strain, the antimicrobials showed lower efficacy in the HI than in the LI
groups: 0.73, 1.89, and 1.62 log10 CFU/g (P < 0.05, for piperacillin-tazobactam, imipenem, and amoxicillin-clavulanate,
respectively, although imipenem and amoxicillin-clavulanate were more efficacious than piperacillin-tazobactam). An adapted
imipenem treatment (based on the time for which the serum drug concentration remained above the MIC obtained with a HI of
the ATCC 25922 strain) improved its efficacy to 1.67 log10 CFU/g (P < 0.05). These results suggest that amoxicillin-clavulanate
could be an alternative to imipenem treatment of infections caused by ESBL- and non-ESBL-producing E. coli strains in patients
with therapeutic failure with piperacillin-tazobactam.
Escheri | es |
dc.format | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | American Society for Microbiology | es |
dc.relation.ispartof | Antimicrobial Agents and Chemotherapy,57(5), 2109–2113 | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Combinación de amoxicilina | es |
dc.subject | Ácido penicilánico | es |
dc.subject | Pruebas de sensibilidad microbiana | es |
dc.subject | Infecciones intraabdominales | es |
dc.subject | Ratones consanguíneos C57BL | es |
dc.subject | Recuento de colonias microbianas clavulanato potásico | es |
dc.subject | Amoxicillin-clavulanate | es |
dc.subject | Escherichia coli | es |
dc.title | Inoculum Effect on the Efficacies of Amoxicillin-Clavulanate, Piperacillin-Tazobactam, and Imipenem against Extended-Spectrum -Lactamase (ESBL)-Producing and Non-ESBL-Producing Escherichia coli in an Experimental Murine Sepsis Model | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Microbiología | es |
dc.relation.publisherversion | http://aac.asm.org/content/57/5/2109 | es |
dc.identifier.doi | http://dx.doi.org/10.1128/AAC.02190-12 | es |
dc.identifier.idus | https://idus.us.es/xmlui/handle/11441/36519 | |